Copyright
©The Author(s) 2018.
World J Gastroenterol. Sep 28, 2018; 24(36): 4152-4163
Published online Sep 28, 2018. doi: 10.3748/wjg.v24.i36.4152
Published online Sep 28, 2018. doi: 10.3748/wjg.v24.i36.4152
Table 1 Predictive and/or prognostic value of clinical markers in hepatocellular carcinoma patients
| Clinical markers | Predictive value | Prognostic value | Ref. |
| Alpha-fetoprotein | No | Yes | [6] |
| Adverse events | |||
| Hand-foot skin reaction | No | Yes | [13] |
| Hypertension | No | Uncertain | [16,19,20] |
| Diarrhea | No | Yes | [21] |
| Child-Pugh A vs B | No | Yes | [27-29] |
| Macroscopic vascular invasion | No | Yes | [6] |
| BCLC B vs C | No | Yes | [6,29,32] |
| Starting dose and dose reduction | No | Yes | [29,32] |
| Etiology HCV vs HBV | Yes | Yes | [6] |
| Chronic treatment with metformin | No | Yes | [35,36] |
| Neutrophil-to-lymphocyte ratio | Yes | Yes | [6,41,44] |
| Extra hepatic spread | Yes | Yes | [6] |
- Citation: Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol 2018; 24(36): 4152-4163
- URL: https://www.wjgnet.com/1007-9327/full/v24/i36/4152.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i36.4152